All In Biotech

Drug Trial Radar · NCT07888699

WST03 Capsule Combined With Metronidazole for Bacterial Vaginosis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled PhaseⅡ Study to Evaluate the Efficacy and Safety of WST03 Capsule Combined With Metronidazole for Bacterial Vaginosis

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Oct 20, 2026

Primary completion

Oct 15, 2027

Study completion Dec 25, 2027

Sponsor

Sponsor type
Industry
First posted
Oct 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 trial enrolling approximately 150 pre-menopausal women with bacterial vaginosis (BV). Participants will be randomized 1:1:1 to three groups. All participants will receive oral metronidazole 0.4 g twice daily for 7 days. In addition, participants will take vaginal capsules (high-dose WST03, low-dose WST03, or matched placebo) once daily for 14 days. The primary endpoint is cumulative BV recurrence rate at Week 12. This trial evaluates the efficacy and safety of WST03 plus metronidazole for lowering BV recurrence and explores its impact on vaginal microecology.

Conditions

  • Bacterial Vaginosis (BV)

Interventions

  • High-dose WST03 Vaginal Capsule MetronidazoleDrug

    High-dose vaginal capsule containing multi-strain live lactobacilli; vaginal administration, once daily for 14 consecutive days (Day 1-14). Metronidazole 0.4 g twice daily for 7 days (Day1-7).

  • Low-dose WST03 Vaginal Capsule MetronidazoleDrug

    Low-dose vaginal capsule containing multi-strain live lactobacilli; vaginal administration, once daily for 14 consecutive days (Day 1-14). Metronidazole 0.4 g twice daily for 7 days (Day1-7).

  • Placebo Vaginal Capsule MetronidazoleDrug

    Placebo vaginal capsule, visually identical to WST03 capsule, vaginal administration, once daily for 14 consecutive days (Day1-14). Metronidazole 0.4 g twice daily for 7 days (Day1-7).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative recurrence rate of bacterial vaginosis (BV) up to Week-12 visitTime frame: From first study drug administration up to Week-12 visit

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Tsinghua Changgung Hospital

    Beijing, Beijing Municipality, China

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Shenzhen University of Technology General Hospital

    Shenzhen, Guangdong, China

  • Liuzhou Maternal and Child Health Hospital

    Liuzhou, Guangxi, China

  • The First Affiliated Hospital of Henan Medical University

    Xinxiang, Henan, China

  • Taihe Hospital, Shiyan City

    Shiyan, Hubei, China

  • Zhuzhou Maternal and Child Health Hospital

    Zhuzhou, Hunan, China

  • The Second Hospital of Jilin University

    Changchun, Jilin, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, China

  • Shanghai First Maternity and Infant Hospital

    Shanghai, Shanghai Municipality, China

  • The Second Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China

  • Chengdu Women's and Children's Central Hospital

    Chengdu, Sichuan, China

  • Women's Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.